ArticleAesthetic plastic surgery2025
Efficacy of Combined Conjoint Fascial Sheath and Levator Muscle Composite Flap Suspension for Recurrent Severe Ptosis.
Article in Aesthetic plastic surgery, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
backgroundConjoint fascial sheath (CFS) and levator muscle (LM) composite flap suspension has been gradually accepted for the treatment of congenital severe blepharoptosis in recent years. This study is to evaluate the clinical efficacy of conjoint fascial sheath with levator muscle (CFS + LM) suspension in the treatment of recurrent severe ptosis.
methodsA total of 45 patients (51 eyes) with recurrent severe ptosis admitted to our hospital between February 2018 and October 2022 were treated with CFS + LM suspension. The surgical efficacy was evaluated by recording and analyzing the distance (in millimeters) from the pupillary reflex on the patient's cornea to the upper eyelid margin (MRD1), palpebral fissure height (PFH), lagophthalmos (LAG), degree of satisfaction and complications.
resultsA total of 45 patients (51 eyes) with recurrent severe ptosis were included in this study, including 26 males and 19 females, with an average age of 23.16 ± 10.68 years. The average levator function was 1.98 ± 1.35 mm, and the average postoperative follow-up time was 19.71 ± 13.77 month. The preoperative MRD1 and PFH were - 0.18 ± 1.03 mm and 3.90 ± 0.88 mm, respectively. Postoperative follow-up was conducted at least 6 months, and the MRD1 and PFH values were 2.25 ± 0.77 mm and 7.04 ± 0.82 mm at the last follow-up, respectively; the differences with the corresponding preoperative values were significant (p< 0.05). All the operated eyes had different degrees of LAG, which also stabilized 6 months after surgery. The treatment was considered curative for 30 eyes (58.82%), to have made improvement in 11 eyes (21.57%), and ineffective for 10 eyes (19.61%). The overall effectiveness (curative + improvement) rate was 80.39%, and the total degree of satisfaction reached 77.78%. After surgery, conjunctival prolapse occurred in 3 patients, 2 of whom recovered after placement of fornix sutures. Conjunctival prolapse in 1 patient disappeared after conservative treatment. Exposure keratitis occurred in 1 patient and improved after drug treatment. No other complications occurred.
conclusionsCFS + LM suspension technique for correcting recurrent severe ptosis is easy to perform, causes minimal trauma, and results in good therapeutic effects and few complications. We recommend popularizing this technique in clinical practice. LEVEL OF EVIDENCE II: This journal requires that authors assign a level of evidence to each article. For a full description of these Evidence-Based Medicine ratings, please refer to the Table of Contents or the online Instructions to Authors www.springer.com/00266 .
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.